Please login to the form below

Not currently logged in
Email:
Password:

Trumenba

This page shows the latest Trumenba news and features for those working in and with pharma, biotech and healthcare.

Pfizer wins EU approval for MenB vaccine Trumenba

Pfizer wins EU approval for MenB vaccine Trumenba

Trumenba has been approved in Europe to prevent MenB in people aged 10 or above, more than four years after Bexsero first got the nod from the EMA. ... The UK-based Meningitis Research Foundation said it welcomed the licensing of Trumenba, with chief

Latest news

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    CHMP recommendations also include Trumenba, Dinutuximab beta and Refixia. MSD and Bristol-Myers Squibb (BMS) both picked up positive opinions for their PD-1 inhibitors from the EMA's advisory committee ... Trumenba has been approved for children aged 10

  • Pfizer posts positive Trumenba vaccine data Pfizer posts positive Trumenba vaccine data

    Pfizer's Trumenba vaccine for meningitis B has shown favourable results in two phase III trials. ... Trumenba was approved by the FDA in 2014 to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B.

  • US expands recommended use of meningitis B vaccines US expands recommended use of meningitis B vaccines

    Butopts not to back routine use of GSK's Bexsero and Pfizer' Trumenba.  . ... But the panel - part of the US Centers for Disease Control and Prevention (CDC) - opted not to recommend routine vaccination with GSK's Bexsero and Pfizer's Trumenba, though

  • Pfizer teams up with snowboarder in meningitis campaign Pfizer teams up with snowboarder in meningitis campaign

    Pfizer's recent developments in meningitis include the FDA approval of its meningitis B vaccine Trumenba in October this year, ahead of a decision on Novartis' rival vaccine Bexsero.

  • Pfizer gets FDA nod for meningitis vaccine Trumenba Pfizer gets FDA nod for meningitis vaccine Trumenba

    Ahead of Novartis’ rival drug Bexsero. Pfizer's Trumenba has become the first vaccine licensed in the US to protection meningitis B (menB), ahead of rival Bexsero from Novartis. ... Pfizer has already generated trial data showing that Trumenba can be

More from news
Approximately 5 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics